Becton, Dickinson and Company (NYSE:BDX) Shares Acquired by Tompkins Financial Corp

Tompkins Financial Corp increased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 333.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 650 shares of the medical instruments supplier’s stock after acquiring an additional 500 shares during the quarter. Tompkins Financial Corp’s holdings in Becton, Dickinson and Company were worth $147,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BDX. First Pacific Financial increased its stake in Becton, Dickinson and Company by 14.4% in the fourth quarter. First Pacific Financial now owns 4,431 shares of the medical instruments supplier’s stock valued at $1,005,000 after purchasing an additional 557 shares during the last quarter. Cypress Wealth Services LLC purchased a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at $714,000. USA Financial Formulas purchased a new position in shares of Becton, Dickinson and Company in the 4th quarter worth $192,000. Apella Capital LLC grew its position in Becton, Dickinson and Company by 16.3% during the fourth quarter. Apella Capital LLC now owns 1,531 shares of the medical instruments supplier’s stock valued at $347,000 after acquiring an additional 215 shares during the period. Finally, Covea Finance increased its stake in Becton, Dickinson and Company by 6.0% during the fourth quarter. Covea Finance now owns 58,625 shares of the medical instruments supplier’s stock worth $13,300,000 after acquiring an additional 3,300 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Finally, Evercore ISI raised their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $283.50.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Roland Goette sold 638 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $219.03, for a total transaction of $139,741.14. Following the completion of the transaction, the executive vice president now directly owns 14,217 shares in the company, valued at approximately $3,113,949.51. This represents a 4.29 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Shana Carol Neal sold 788 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total transaction of $185,180.00. Following the completion of the sale, the executive vice president now owns 16,201 shares of the company’s stock, valued at approximately $3,807,235. This trade represents a 4.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 8,747 shares of company stock worth $1,949,520 in the last 90 days. 0.36% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $236.23 on Friday. The firm has a market capitalization of $68.51 billion, a PE ratio of 39.77, a price-to-earnings-growth ratio of 1.69 and a beta of 0.39. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $248.42. The stock’s 50 day moving average price is $226.77 and its 200 day moving average price is $232.51. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. The business had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same period in the previous year, the company posted $3.42 earnings per share. As a group, sell-side analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 31st. Investors of record on Monday, December 9th were issued a $1.04 dividend. The ex-dividend date was Monday, December 9th. This represents a $4.16 dividend on an annualized basis and a yield of 1.76%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio is currently 70.03%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.